{
  "pmcid": "6868305",
  "sha256": "ee48e06b6f986b9a84be03fdbde48c13fa32cb32939d4202a7a4f8b6f2ee8811",
  "timestamp_utc": "2025-11-09T22:52:19.909106+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.526842427958307,
    "reading_ease": 32.182775393419206,
    "word_count": 233
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "A multicenter, cooperative group, single-arm phase II trial (ACOSOG Z5041)"
      },
      "Participants": {
        "score": 2,
        "evidence": "Patients with biopsy-confirmed PDAC in the pancreatic head without major mesenteric vessel involvement were eligible."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants received an eight-week cycle of G+E before and after surgery."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluated the feasibility of perioperative gemcitabine plus erlotinib (G+E) for resectable pancreatic ductal adenocarcinoma (PDAC)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary endpoint was two-year overall survival (OS)."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "One hundred fourteen patients were eligible, consented, and initiated protocol treatment."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Fifty-four completed postoperative G+E (65%)."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The two-year OS rate for the entire cohort was 40% (95% CI 31–50) with a median OS of 21.3 months (95% CI 17.2–25.9)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Grade 3+ toxicity was reported in 60% during the neoadjuvant phase and 79% overall."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT01004314."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: National Cancer Institute."
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}